Lehrstuhl für Haut- und Geschlechtskrankheiten

Dendritic cells are involved in the resolution of inflammation by IVIg in arthritis (2022) Lehmann C, Amon L, Seichter A, Brückner C, Altmann L, Heger L, Heger L, et al. Conference contribution Spatial, structural and density determinants of DC:T cell interaction under immunostimulatory conditions (2022) Vurnek D, Amon L, Buttazzo L, Lehmann C, Zaburdaev V, Dudziak D Conference contribution Environment affects dendritic cells' response via Aryl Hydrocarbon Receptor ligands: a comparison between endogenous and exogenous ligands (2022) Sadeghi Shermeh A, Wild A, Michalski J, Steinkasserer A Conference contribution A cross-tissue protein profiling atlas reveals distinct cDC2 subpopulations within the murine conventional dendritic cell network (2022) Amon L, Lehmann C, Seichter A, Heger L, Dudziak D Conference contribution Eine übermäßige Phagozytose von Myelomzellen induziert Pyroptose in Myelom-assoziierten Makrophagen und beeinträchtigt die Wirksamkeit therapeutischer Antikörper (2022) Flamann C, Biedermann A, Mougiakakos D, Bitterer K, Karg K, Bittenbring J, Büttner-Herold M, et al. Conference contribution Single-cell Transcriptome Analysis and clonal Kinetics in a Patient after CD19.CAR-T Cell Therapy (2022) Lischer C, Eisenhauer N, Aigner M, Jacobs B, Schletter M, Gebhard C, Rehli M, et al. Conference contribution Real-world clinical outcomes of pembrolizumab for advanced melanoma in the German ADOREG skin cancer registry (2022) Mohr P, Scherrer E, Alar V, Assaf C, Beissert S, Berking C, Eigentler T, et al. Conference contribution Predictors of long-term survival of stage IV melanoma patients: a multicenter DeCOG study on 539 patients from the prospective skin cancer registry ADOREG (2022) Placke JM, Mohr P, Bluhm L, Kahler K, Weichenthal M, Meier F, Garzarolli M, et al. Conference contribution Therapy Management of the first Recurrence after adjuvant Therapy in Stage III: multicenter real-world Data (2022) Lodde G, Forschner A, Hassel JC, Wulfken LM, Meier F, Mohr P, Kaehler K, et al. Conference contribution Effectiveness and Safety of Dabrafenib and Trametinib in Patients with BRAFV600 Mutated Metastatic Melanoma in the Real-World Setting - Final Results of the Non-Interventional COMBI-r Study (2022) Berking C, Livingstone E, Weichenthal M, Leiter-Stoeppke U, Remy J, Eigentler T, Mohr P, et al. Conference contribution